Welcome to Medications.com

Singulair associated with Churg-Strauss. A study in France and Ge...

Posted at 8:11 AM on Jul 31, 2008 by concernedcitizen, #32903
Singulair associated with Churg-Strauss. A study in France and Germany. Thorax. 2008 Aug;63(8):677-82. Epub 2008 Feb 14. Links The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study.Hauser T, Mahr A, Metzler C, Coste J, Sommerstein R, Gross WL, Guillevin L, Hellmich B. Dr A Mahr, Department of Internal Medicine, Hôpital Cochin, 27 rue du Faubourg Saint-Jacques, 75679 Paris Cedex 14, France. alfred.mahr@cch.aphp.fr. BACKGROUND: There has been some concern that leucotriene receptor antagonists might precipitate the onset of Churg-Strauss syndrome (CSS). A study was undertaken to investigate the relationship between the leucotriene receptor antagonist montelukast and the onset of CSS. METHODS: Medication histories of 78 patients with CSS from France and Germany were retraced by questioning the patients, treating physicians and dispensing pharmacists, and from medical records. Using a case-crossover research design, exposures to montelukast and other asthma medications during the 3-month "index" period immediately preceding the onset of CSS were compared with those of four previous 3-month "control" periods. Odds ratios (ORs) were computed by conditional logistic regression. RESULTS: The ORs for CSS onset were 4.5 (95% CI 1.5 to 13.9) for montelukast, 3.0 (95% CI 0.8 to 10.5) for inhaled long-acting beta(2) agonists, 1.7 (95% CI 0.5 to 5.4) for inhaled corticosteroids and 4.0 (95% CI 1.3 to 12.5) for oral corticosteroids. Montelukast exposure during control periods increased temporally over three consecutive calendar periods of CSS onset from 1999 to 2003 (p(trend) <0.0001). CONCLUSION: Montelukast use was associated with a 4.5-fold higher risk of CSS onset within 3 months. However, the positive estimates obtained for other long-term asthma control medications suggest that this link might be confounded by a general escalation of asthma therapy before CSS onset. The association between montelukast and CSS observed in this study is probably also explained by the increasing use of this medication over time. PMID: 18276721 [PubMed - in process]
REPLY TO THIS POSTING | Private Message me | Add as friend | Flag as inappropriate
 
Reply about 1 year ago on Jul 31, 2008 by kate2, #10641

Hi,
I am so relieved to see your post, welcome back I thought something was wrong when I did not see you post for so long! Dr. Sarah Sellers is done with her review and is leaving the FDA. I recieved a phone call from her last week,other people are still working on the next level of review.When I spoke with her she said she worked hard on her end and that it was on schedule.I am again so appreciative of all your research.
Kate Miller

Private Message me | Add as friend | Flag as inappropriate

Make a reply to this posting:

Type your reply to this side effect post:


Medical advice disclaimer
© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com | Sleep Apnea